Real-world safety of rapid 30-minute intravenous isatuximab infusion in multiple myeloma: results from the largest published cohort

1

Isatuximab is an anti-CD38 monoclonal antibody used in multiple myeloma, traditionally requiring a 75-minute intravenous infusion.
2

A multicenter study across 9 Spanish hospitals evaluated the safety of a rapid 30-minute intravenous isatuximab infusion in 103 patients.
3

Only 1 infusion-related reaction (IRR) was recorded during 1,344 rapid infusions, resulting in a per-patient rate of 0.97%.
4

Of the 22 patients with prior IRRs at standard rate, 21 completed the rapid infusion protocol without reverting to standard rate.
5

The rapid infusion protocol resulted in an estimated 1,008 hours of cumulative day-hospital chair time savings.

Frontiers In Oncology

by Xabier Gutiérrez López De Ocáriz, Ernesto Pérez Persona, Laura Salcedo Cuesta, Eusebio Martín Chacón, Maialen Sirvent Auzmendi, Pamela Millacoy Austerrritt, Marcos Lorenzo Pérez, Elena Landete Hernández, Vicente Carrasco Baraja, Irene Sanchéz Romero, Tania Ivett Arámbula, Ianire Etxeguren Urkixo
July 9, 2026

1